Last reviewed · How we verify
NCT04336618: DFWRegistry
Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population
trial testing Liver MultiScan in Non-Alcoholic Fatty Liver Disease in 67 participants. Completed in 27 September 2022.
27 September 2022
Quick facts
| Lead sponsor | Perspectum |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 67 |
| Start date | 3 August 2020 |
| Primary completion | 27 September 2022 |
| Estimated completion | 27 September 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Liver MultiScan
Conditions studied
- Non-Alcoholic Fatty Liver Disease — all drugs for Non-Alcoholic Fatty Liver Disease →
Sponsor
Perspectum
Who can join
18 and older, any sex, with Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To build a Registry of volunteers by inviting them to get a LiverMultiScan(LMS)and collecting their contact information to seek interest in participating in future studies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04336618
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Alcoholic Fatty Liver Disease
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
- NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
- NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
- NCT06863376 — Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients · Phase 2 · recruiting
Other Perspectum trials
Trials by the same sponsor.
- NCT07098650 — Haemdall: Developing a Quantitative MRI Biomarker of Infratentorial Superficial Siderosis of the Central Nervous System · recruiting
- NCT04974710 — Developing an US-MRI Biomarker Fusion Model for Endometriosis · completed
- NCT05326191 — First-trimester Placental Ultrasound Study · completed
- NCT05000242 — West Hertfordshire Inflammatory Bowel Disease Technology Study · active not recruiting
- NCT05110248 — Research and Development of Novel Quantitative Magnetic Resonance Imaging (MRI) Techniques in a Single Scan for Multiple · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04336618 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Perspectum
- Last refreshed: 22 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04336618.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing